These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 31621838)

  • 1. Antiretroviral Therapy-Induced Bone Loss Is Durably Suppressed by a Single Dose of Zoledronic Acid in Treatment-Naive Persons with Human Immunodeficiency Virus Infection: A Phase IIB Trial.
    Ofotokun I; Collins LF; Titanji K; Foster A; Moran CA; Sheth AN; Lahiri CD; Lennox JL; Ward L; Easley KA; Weitzmann MN
    Clin Infect Dis; 2020 Oct; 71(7):1655-1663. PubMed ID: 31621838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Single-dose Zoledronic Acid Infusion Prevents Antiretroviral Therapy-induced Bone Loss in Treatment-naive HIV-infected Patients: A Phase IIb Trial.
    Ofotokun I; Titanji K; Lahiri CD; Vunnava A; Foster A; Sanford SE; Sheth AN; Lennox JL; Knezevic A; Ward L; Easley KA; Powers P; Weitzmann MN
    Clin Infect Dis; 2016 Sep; 63(5):663-671. PubMed ID: 27193748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
    J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study.
    Hadji P; Kauka A; Ziller M; Birkholz K; Baier M; Muth M; Bauer M
    Osteoporos Int; 2014 Apr; 25(4):1369-78. PubMed ID: 24504100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.
    Sambrook PN; Roux C; Devogelaer JP; Saag K; Lau CS; Reginster JY; Bucci-Rechtweg C; Su G; Reid DM
    Bone; 2012 Jan; 50(1):289-95. PubMed ID: 22061864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
    Orwoll ES; Miller PD; Adachi JD; Brown J; Adler RA; Kendler D; Bucci-Rechtweg C; Readie A; Mesenbrink P; Weinstein RS
    J Bone Miner Res; 2010 Oct; 25(10):2239-50. PubMed ID: 20499357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic efficacy of zoledronic acid combined with calcitriol in elderly patients receiving total hip arthroplasty or hemiarthroplasty for osteoporotic femoral neck fracture.
    Zhu K; Zhang J; Zhang C; Zhao Z; Gao J; Li X; Xia X; Xu X; Zhang T; Guan J
    Osteoporos Int; 2021 Mar; 32(3):559-564. PubMed ID: 32989470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study.
    Liang BC; Shi ZY; Wang B; Wu P; Kong LC; Yao JL; Li CW; Shi XL
    Orthop Surg; 2017 Feb; 9(1):103-109. PubMed ID: 28276638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).
    Black DM; Reid IR; Boonen S; Bucci-Rechtweg C; Cauley JA; Cosman F; Cummings SR; Hue TF; Lippuner K; Lakatos P; Leung PC; Man Z; Martinez RL; Tan M; Ruzycky ME; Su G; Eastell R
    J Bone Miner Res; 2012 Feb; 27(2):243-54. PubMed ID: 22161728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density.
    Eastell R; Black DM; Boonen S; Adami S; Felsenberg D; Lippuner K; Cummings SR; Delmas PD; Palermo L; Mesenbrink P; Cauley JA;
    J Clin Endocrinol Metab; 2009 Sep; 94(9):3215-25. PubMed ID: 19567517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with Zoledronate Subsequent to Denosumab in Osteoporosis: a Randomized Trial.
    Sølling AS; Harsløf T; Langdahl B
    J Bone Miner Res; 2020 Oct; 35(10):1858-1870. PubMed ID: 32459005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. THE CLINICAL CHARACTERISTICS AND EFFICACY OF BISPHOSPHONATES IN AUDLT PATIENTS WITH OSTEOGENESIS IMPERGECTA.
    Xu XJ; Ma DD; Lv F; Wang JY; Liu Y; Xia WB; Jiang Y; Wang O; Xing XP; Yu W; Li M
    Endocr Pract; 2016 Nov; 22(11):1267-1276. PubMed ID: 27482615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged Effect of Zoledronic Acid on Bone Mineral Density and Turnover in HIV-Infected Adults on Tenofovir: A Randomized, Open-Label Study.
    Carr A; Kerr SJ; Richardson R; Ebeling P; Pocock N; Rojas J; Martinez E; Hoy J;
    J Bone Miner Res; 2019 Dec; 34(12):2192-2197. PubMed ID: 31361922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates.
    Miller PD; Pannacciulli N; Brown JP; Czerwinski E; Nedergaard BS; Bolognese MA; Malouf J; Bone HG; Reginster JY; Singer A; Wang C; Wagman RB; Cummings SR
    J Clin Endocrinol Metab; 2016 Aug; 101(8):3163-70. PubMed ID: 27270237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial.
    Crawford BA; Kam C; Pavlovic J; Byth K; Handelsman DJ; Angus PW; McCaughan GW
    Ann Intern Med; 2006 Feb; 144(4):239-48. PubMed ID: 16490909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment.
    Hershman DL; McMahon DJ; Crew KD; Shao T; Cremers S; Brafman L; Awad D; Shane E
    J Clin Endocrinol Metab; 2010 Feb; 95(2):559-66. PubMed ID: 20022990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy.
    Kalder M; Kyvernitakis I; Albert US; Baier-Ebert M; Hadji P
    Osteoporos Int; 2015 Jan; 26(1):353-60. PubMed ID: 25381047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial.
    McClung M; Miller P; Recknor C; Mesenbrink P; Bucci-Rechtweg C; Benhamou CL
    Obstet Gynecol; 2009 Nov; 114(5):999-1007. PubMed ID: 20168099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.
    Anastasilakis AD; Polyzos SA; Efstathiadou ZA; Savvidis M; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
    Metabolism; 2015 Oct; 64(10):1291-7. PubMed ID: 26198440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.